Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, placebo controlled pivotal trial of Ezutromid in patients

Trial Profile

A randomised, placebo controlled pivotal trial of Ezutromid in patients

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2018

At a glance

  • Drugs Ezutromid (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Registrational; Therapeutic Use
  • Sponsors Summit Therapeutics
  • Most Recent Events

    • 27 Jun 2018 According to a Summit Therapeutics media release, based on the results of the PhaseOut DMD 48-week data, the company has discontinued this drug development program, as, its primary and secondary endpoints has not been Met.
    • 27 Jun 2018 Status changed from planning to withdrawn prior to enrolment, according to a Summit Therapeutics media release.
    • 29 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top